← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) 10-Year Financial Performance & Capital Metrics

RZC • • Insurance & Managed Care
Financial ServicesDiversified InsuranceSpecialty & ReinsuranceSpecialty Risk & Reinsurance
AboutReinsurance Group of America, Inc. is a holding company, which engages in the provision of traditional and non-traditional life and health reinsurance products. It operates through the following segments: U.S. and Latin America, Canada, Europe, Middle East, and Africa, Asia Pacific, and Corporate and Other. The U.S. and Latin America segment markets individual and group life and health reinsurance to domestic clients for a variety of products through yearly renewable term agreements, coinsurance, and modified coinsurance. The Canada segment offers individual life reinsurance, and, to a lesser extent, creditor, group life and health, critical illness, and disability reinsurance, through yearly renewable term and coinsurance agreements. The Europe, Middle East, and Africa segment serves individual and group life and health products through yearly renewable term and coinsurance agreements, reinsurance of critical illness coverage that provides a benefit in the event of the diagnosis of a pre-defined critical illness, and underwritten annuities. The Asia Pacific segment consists of individual and group life and health reinsurance, critical illness coverage, disability, and superannuation through yearly renewable term and coinsurance agreements. The Corporate and Other segment consists of investment income from unallocated invested assets, investment related gains, and losses and service fees. The company was founded in 1973 and is headquartered in Chesterfield, MO.Show more
  • Revenue $22.04B +19.9%
  • Combined Ratio 95.55% +2.0%
  • Net Income $717M -20.5%
  • Return on Equity 7.14% -35.3%
  • Medical Cost Ratio 88.71% +1.6%
  • Operating Margin 4.45% -29.5%
  • Net Margin 3.25% -33.7%
  • ROA 0.66% -32.9%
  • Equity / Assets 9.19% -2.2%
  • Book Value per Share 163.02 +19.3%
  • Tangible BV/Share 161.03 +19.8%
  • Debt/Equity 0.46 -4.2%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓17 consecutive years of dividend growth
  • ✓Trading near 52-week high
  • ✓Trading at only 0.2x book value

✗Weaknesses

  • ✗High loss ratio of 88.7%

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y7.29%
5Y9.19%
3Y11.13%
TTM2.28%

Profit (Net Income) CAGR

10Y0.47%
5Y-3.79%
3Y-15.06%
TTM19.26%

EPS CAGR

10Y0.93%
5Y-4.66%
3Y5.88%
TTM-80.17%

ROCE

10Y Avg1.39%
5Y Avg1.05%
3Y Avg1%
Latest0.91%

Peer Comparison

Specialty Risk & Reinsurance
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
IGICInternational General Insurance Holdings Ltd.1.04B24.018.0610.24%23.05%19.02%19.57%0.01
RZC7.125% Fixed-Rate Reset Subordinated Debentures due 205225.472.3719.85%3.89%6.63%0.46
FGNXFG Nexus Inc.121.1M3.06-1.261.49%-6.66%-7.05%0.05

Profit & Loss

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Revenue+10.42B11.52B12.52B12.88B14.2B14.58B16.06B15.88B18.39B22.04B
Revenue Growth %-0.04%0.11%0.09%0.03%0.1%0.03%0.1%-0.01%0.16%0.2%
Medical Costs & Claims+8.95B9.67B10.49B11.07B12.1B13.04B14.21B14.31B16.06B19.55B
Medical Cost Ratio %----------
Gross Profit+1.46B1.85B2.03B1.81B2.1B1.54B1.85B1.57B2.33B2.49B
Gross Margin %----------
Gross Profit Growth %-0.12%0.27%0.09%-0.11%0.16%-0.27%0.2%-0.15%0.48%0.07%
Operating Expenses+719.55M808.96M885M963M969M991M469M853M1.17B1.51B
OpEx / Revenue %----------
Depreciation & Amortization31.1M26.85M53M45M49M49M43M38M41M46M
Combined Ratio %----------
Operating Income+744.79M1.04B1.14B846M1.13B553M1.39B718M1.16B980M
Operating Margin %----------
Operating Income Growth %-0.26%0.4%0.09%-0.26%0.34%-0.51%1.5%-0.48%0.62%-0.16%
EBITDA+775.9M1.07B1.2B891M1.18B602M1.43B756M1.2B1.03B
EBITDA Margin %----------
Interest Expense142.86M137.62M146M147M173M170M139M191M257M304M
Non-Operating Income-142.86M-137.62M-146M-147M-173M-170M-139M-191M-257M-304M
Pretax Income+744.79M1.04B1.14B846M1.13B553M1.39B718M1.16B980M
Pretax Margin %----------
Income Tax+242.63M342.5M-679M130M262M138M215M197M251M256M
Effective Tax Rate %----------
Net Income+502.17M701.44M1.82B716M870M415M1.17B517M902M717M
Net Margin %----------
Net Income Growth %-0.27%0.4%1.6%-0.61%0.22%-0.52%1.82%-0.56%0.74%-0.21%
EPS (Diluted)+7.4610.7927.7111.0013.626.319.047.6413.4410.73
EPS Growth %-0.24%0.45%1.57%-0.6%0.24%-0.54%0.43%-0.15%0.76%-0.2%
EPS (Basic)7.5510.9128.2811.2513.886.359.107.7313.6010.90
Diluted Shares Outstanding67.29M64.99M65.75M65.09M63.88M65.8M68.3M67.7M67.1M66.9M

Balance Sheet

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Assets+50.38B53.1B60.51B64.53B76.73B84.66B92.17B84.9B97.62B118.67B
Asset Growth %0.13%0.05%0.14%0.07%0.19%0.1%0.09%-0.08%0.15%0.22%
Total Investment Assets+41.98B44.84B51.69B54.28B60.63B66.68B121.82B64.48B2.73B98.04B
Long-Term Investments11.78B12.67B13.45B14.14B52.64B58.46B60.99B55.52B-57.96B95.86B
Short-Term Investments30.2B32.17B38.24B40.13B8.62B8.37B60.84B7.82B60.69B2.18B
Total Current Assets+1.53B34.06B1.3B42.78B0066.36B02.97B11.04B
Cash & Equivalents1.53B1.2B1.3B1.89B1.45B3.41B2.95B2.93B2.97B3.33B
Receivables1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K
Other Current Assets0000-10.97B-12.76B0-13.42B-66.14B0
Goodwill & Intangibles+81.2M71.3M59.3M85.2M230M213M193M164M154M133M
Goodwill7M7M7M7M7M7M7M000
Intangible Assets74.2M64.3M52.3M78.2M223M206M186M164M154M133M
PP&E (Net)-13.14B000244M260M284M270M279M325M
Other Assets34.78B39.15B45.7B48.42B-53.11B-58.93B-14M-55.95B140.63B11.32B
Total Liabilities44.25B46B50.95B56.09B65.13B70.3B79.16B77.73B88.45B107.77B
Total Debt+3.2B3.93B3.57B3.47B3.98B4.36B3.85B4.36B4.43B5.04B
Net Debt1.67B2.73B2.27B1.58B2.53B953M899M1.43B1.46B1.72B
Long-Term Debt3.2B3.93B3.57B3.47B3.58B3.96B3.85B3.96B4.43B5.04B
Short-Term Debt0000400M400M0400M00
Total Current Liabilities+296.9M688.93M488.74M487M000000
Accounts Payable637.86M388.99M488.74M487M557M598M613M756M00
Deferred Revenue000000213M000
Other Current Liabilities-296.9M299.94M-488.74M-487M-957M-998M-826M-1.89B-4.48B-5.02B
Deferred Taxes1000K1000K1000K01000K1000K1000K1000K1000K1000K
Other Liabilities38.83B38.62B45.17B52.62B-6.29B-7.22B72.43B-5.34B82.16B100.53B
Total Equity+6.14B7.09B9.57B8.45B11.6B14.35B13.01B7.17B9.17B10.91B
Equity Growth %-0.13%0.16%0.35%-0.12%0.37%0.24%-0.09%-0.45%0.28%0.19%
Shareholders Equity6.14B7.09B9.57B8.45B11.6B14.35B13.01B7.08B9.08B10.82B
Minority Interest000000090M90M90M
Retained Earnings4.62B5.2B6.74B7.28B7.95B8.15B8.56B8.17B8.8B9.26B
Common Stock791K791K791K791K1M1M1M1M1M1M
Accumulated OCI708.28M1.14B2.06B636.76M3.14B5.36B3.64B-1.87B-369M849M
Return on Equity (ROE)0.08%0.11%0.22%0.08%0.09%0.03%0.09%0.05%0.11%0.07%
Return on Assets (ROA)0.01%0.01%0.03%0.01%0.01%0.01%0.01%0.01%0.01%0.01%
Equity / Assets----------
Debt / Equity0.52x0.55x0.37x0.41x0.34x0.30x0.30x0.61x0.48x0.46x
Book Value per Share91.18109.14145.54129.82181.60218.12190.54105.92136.68163.02
Tangible BV per Share----------

Cash Flow

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+2.09B1.47B1.98B1.58B2.31B3.32B4.18B1.34B4.04B9.37B
Operating CF Growth %-0.11%-0.3%0.35%-0.2%0.46%0.44%0.26%-0.68%2.01%1.32%
Operating CF / Revenue %----------
Net Income502.17M701.44M1.82B715.84M870M415M617M517M902M717M
Depreciation & Amortization31.1M26.85M53M45.13M49M3M-11M38M41M46M
Stock-Based Compensation000039M00000
Deferred Taxes149M0076.51M0-16M0000
Other Non-Cash Items-13.25M136.49M-249.14M5.38M-31M-62M-731M346M-116M343M
Working Capital Changes1.42B600.93M356.27M738.26M1.38B2.98B4.31B442M3.22B8.26B
Cash from Investing+-1.43B-2.83B-1.61B-636.55M-2.64B-2.68B-4.63B-5.69B-4.07B-12.54B
Capital Expenditures-23.55M-44.64M-44.21M-28.89M-34M-28M-19M-25M00
Acquisitions-145.24M00-31.44M4M-173M-287M17M-77M-320M
Purchase of Investments-6.21B-8.1B-8.94B-10.1B-16.28B-10.26B-18.28B-17.07B-13.25B-41.69B
Sale/Maturity of Investments1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K
Other Investing-1.12B-641.52M-657.07M-615.69M-442M115M129M-60M711M-1.03B
Cash from Financing+-708.28M1.06B-324.62M-321.97M-121M1.25B20M4.44B78M3.66B
Dividends Paid-93.38M-100.37M-117.29M-140.11M-163M-182M-194M-205M-219M-229M
Share Repurchases-384.52M-122.92M-44M-299.68M-101M-163M-99M-81M-227M-27M
Stock Issued00000481M0000
Debt Issuance (Net)1000K1000K-1000K-1000K1000K1000K-1000K1000K1000K1000K
Other Financing-372.49M545.74M207.67M217.14M38M737M430M4.62B62M3.31B
Net Change in Cash+-120.39M-324.56M102.81M586.21M-441M1.96B-460M-21M43M356M
Exchange Rate Effect-1000K-1000K1000K-1000K1000K1000K-1000K-1000K-1000K-1000K
Cash at Beginning1.65B1.53B1.2B1.3B1.89B1.45B3.41B2.95B2.93B2.97B
Cash at End1.53B1.2B1.3B1.89B1.45B3.41B2.95B2.93B2.97B3.33B
Free Cash Flow+2.07B1.42B1.94B1.55B2.27B3.29B4.16B1.34B4.04B9.37B
FCF Growth %-0.08%-0.31%0.36%-0.2%0.46%0.45%0.26%-0.68%2.01%1.32%
FCF Margin %----------
FCF per Share30.6921.8729.4823.8535.5850.0660.9519.8460.27140.06

Key Ratios

Metric2015201620172018201920202021202220232024
Combined Ratio92.85%90.94%90.87%93.43%92.03%96.21%91.38%95.48%93.69%95.55%
Medical Cost Ratio85.94%83.92%83.8%85.95%85.2%89.41%88.46%90.11%87.33%88.71%
Return on Equity (ROE)7.63%10.61%21.87%7.95%8.68%3.2%8.55%5.12%11.04%7.14%
Return on Assets (ROA)1.06%1.36%3.21%1.15%1.23%0.51%1.32%0.58%0.99%0.66%
Equity / Assets12.18%13.36%15.81%13.09%15.12%16.95%14.12%8.45%9.39%9.19%
Book Value / Share91.18109.14145.54129.82181.6218.12190.54105.92136.68163.02
Debt / Equity0.52x0.55x0.37x0.41x0.34x0.30x0.30x0.61x0.48x0.46x
Revenue Growth-4.46%10.59%8.63%2.88%10.27%2.71%10.13%-1.13%15.82%19.85%

Revenue by Segment

202220232024
Other Operating--8.43B
Other Operating Growth---
Corporate and Other207M335M-
Corporate and Other Growth-61.84%-
US Traditional Reporting Information6.59B--
US Traditional Reporting Information Growth---
Canada Traditional Reporting Information1.22B--
Canada Traditional Reporting Information Growth---
Canada Non-Traditional Reporting Information95M--
Canada Non-Traditional Reporting Information Growth---
US Non-Traditional Reporting Information66M--
US Non-Traditional Reporting Information Growth---

Revenue by Geography

202220232024
Americas8.73B10.45B7.5B
Americas Growth-19.68%-28.21%
Asia Pacific3.3B3.7B3.01B
Asia Pacific Growth-12.16%-18.54%
EMEA2.45B2.5B2B
EMEA Growth-2.12%-20.08%
CANADA1.57B1.58B1.29B
CANADA Growth-0.64%-18.29%

Frequently Asked Questions

Valuation & Price

7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) has a price-to-earnings (P/E) ratio of 2.4x. This may indicate the stock is undervalued or faces growth challenges.

Growth & Financials

7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) grew revenue by 19.9% over the past year. This is strong growth.

Yes, 7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) is profitable, generating $867.0M in net income for fiscal year 2024 (3.3% net margin).

Dividend & Returns

Yes, 7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) pays a dividend with a yield of 13.44%. This makes it attractive for income-focused investors.

7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) has a return on equity (ROE) of 7.1%. This is below average, suggesting room for improvement.

Industry Metrics

7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) has a combined ratio of 95.6%. A ratio below 100% indicates underwriting profitability.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.